51. Beyond Weight Loss: GLP-1s, Inflammation, and Thyroid Health With McCall McPherson, PA-C

What if the GLP-1 conversation is bigger than weight loss?

In this episode, I sit down with McCall McPherson, PA-C, thyroid expert and founder of Modern Thyroid Clinic. We have a candid, nuanced discussion about GLP-1 receptor agonists, the clinical questions that extend beyond the scale, and why safety, nutrition, medication sourcing, and individualized follow-up must stay at the center of the conversation.

McCall shares the clinical observations that led her team to explore low-dose approaches with some thyroid patients, including questions around inflammation and autoimmune symptoms. We also discuss what is established, what remains under study, and why an episode conversation should never replace a personal discussion with a licensed clinician.

Important clinical note: The episode includes discussion of microdosing and possible anti-inflammatory applications. These ideas may be outside FDA-approved uses and are not a plan for self-treatment. Do not start, stop, split, or change a prescription medicine without guidance from a qualified prescriber.

🔥What you will learn in this episode:

📍 What GLP-1 receptor agonists are designed to do and why product-specific labels matter

📍How McCall defines microdosing in her clinical practice and why this approach requires clinician oversight

📍Why inflammation, thyroid symptoms, nutrition, muscle health, and side effects need to be considered together

📍How to approach the thyroid cancer boxed warning with a thoughtful risk-benefit conversation

📍What the FDA-approved cardiovascular indication for Wegovy does and does not tell us about other health claims

📍Why the episode treats cancer, autoimmune disease, and brain-health topics as active areas of discussion and research rather than promises of treatment

📍Why unverified online sources and do-it-yourself dosing can create avoidable safety risks